The pathology and pathogenesis of emphysema are reviewed, with particular reference to the proteinase-antiproteinase hypothesis.

Leukocyte kinetics in the lung
Leukocyte accumulation in the lung is a feature of emphysema (see below). The traffic of leukocytes through the lung microvessels and their migration out of the vascular space through the tissue and into the airspaces is incompletely understood. The pulmonary circulation receives the entire output of the right ventricle—that is, \( \sim 6 \) l/min or 8600 l blood in 24 hours. As each litre of blood contains 10\(^5\) leukocytes, the lung receives approximately 8.6 \(\times\) 10\(^6\) leukocytes every 24 hours. The bronchial circulation adds approximately 1% of the left ventricle output to this value and this increases in disease. The neutrophils are the easiest to keep track of because they do not divide after they enter the circulation from the bone marrow, normally remain inside the vascular space, and do not re-enter the circulation after they migrate out of the microvasculature. The maximum diameter of the circulating cells is slightly larger than the average capillary but, because the disc shaped erythrocytes are able to fold, they are much more deformable than the spherically shaped leukocytes. This allows erythrocytes to move through restrictions in lung capillaries much more quickly than leukocytes, and the multisegmented nature of the lung capillaries allows the faster moving erythrocytes to pass the slower moving neutrophils. This difference between erythrocyte and leukocyte transit time concentrates the neutrophils with respect to the erythrocytes in the lung capillaries and accounts for the so-called margined pool of neutrophils in the pulmonary circulation. Cigarette smoking increases the number of margined neutrophils in the lung capillary bed. Only a very small proportion of circulating neutrophils delivered to the lung ever migrates out of the vascular space, even in the presence of strong stimuli such as pneumococcal pneumonia.

Walker and colleagues have shown that the surface of interstitial fibroblasts form a network that guides the neutrophil from its point of exit out of the capillary to the point of entry into the alveolar airspace. Their work suggests an important interaction between the leukocytes and the...
PATHOGENESIS

Many processes appear to be involved in the pathogenesis of emphysema associated with cigarette smoking [fig 2], but the proteinase-antiproteinase hypothesis has sustained as the central theme for nearly 40 years. According to this hypothesis, destruction of alveolar walls results from proteinase activity that digests extracellular matrix (ECM). The proteinase-antiproteinase hypothesis has considerable experimental support, but many specifics remain unsettled such as the cell types and proteinases responsible for ECM destruction and the ECM component(s) that are targets of the proteinases.

Mice are proving to be valuable in analysing the pathogenesis of emphysema associated with cigarette smoking. Animal models based on the mouse allow early stages of lung injury to be evaluated, where various therapeutic or other types of regimens can be imposed over relatively short experimental periods. Genetic manipulations can be readily accomplished allowing the role of specific gene products to be evaluated. Clearly, genetic factors are critical in the predisposition to emphysema from cigarette smoke exposure in mice. Differences in resistance to developing smoke induced emphysema between several strains of mice, for example, correlate with differences between the strains in the capacity to mount antioxidant responses to cigarette smoke. In contexts other than smoking, mice have been informative about mechanisms of emphysema and, at times, emphysema has been an unexpected finding in genetically abnormal mice.

What cells are responsible for ECM degradation in emphysema?
The idea that emphysema results from chronic inflammation affecting alveoli and terminal airways has dominated this field ever since the discovery linking emphysema and α1-antitrypsin deficiency to neutrophil elastase (NE). Because NE is expressed almost exclusively by neutrophils, and because smokers have more neutrophils in their bronchoalveolar lavage (BAL) fluid than non-smokers, neutrophils have long been considered a major culprit in causing emphysema. However, macrophages, T lymphocytes, and eosinophils are increasingly being implicated in the pathogenesis of lung destruction in emphysema, and some data even suggest that the presence of neutrophils in alveolar walls in smokers correlates with preservation rather than destruction of alveolar walls. A recent analysis of inflammatory cells in the lung parenchyma and terminal airspaces in surgically resected lungs having no emphysema, mild emphysema, or severe emphysema found increased numbers of neutrophils, macrophages, T lymphocytes, and eosinophils in emphysematous tissue. The numbers of each inflammatory cell type correlated equally well with the severity of emphysema so that, by cell numbers, no one type of inflammatory cell appeared to predominate. Compared with normal lung, lungs with severe emphysema contained approximately 10 times more of each of the inflammatory cell types.

These results show that a complex inflammatory response exists in the emphysematous lung. Precisely how the various
inflammatory cell types contribute to the destruction of alveolar walls is yet to be determined, but a reasonable speculation would be that neutrophils, macrophages, and eosinophils degrade alveolar ECM directly by releasing proteinases whereas T lymphocytes influence inflammatory cell recruitment and the function of inflammatory cells that release proteinases. The remarkable expansion of the alveolar macrophage population in many smokers’ lungs may be important in producing alveolar destruction, even though proteinase release per cell may be similar between smokers with emphysema and smokers who do not have emphysema. An intriguing feature of these recent data is that the markedly increased number of inflammatory cells in severe emphysema is present even in individuals who had stopped smoking years earlier. This finding fits with the clinical situation of progressive deterioration of lung function among some former smokers with COPD. The mechanisms that perpetuate recruitment of inflammatory cells in lung tissue long after the primary stimulus—namely, cigarette smoke—has been removed are not known, but peptides derived from ECM are chemotactic for inflammatory cells which suggests that destruction of ECM may be self-perpetuating.

Inflammatory cells may not be the only source of proteinases that degrade alveolar septal ECM. Alveolar epithelial cells in lungs removed for lung transplantation for COPD and in lung tissues resected at lung volume reduction surgery express the collagenase matrix metalloproteinase 1 (MMP-1) mRNA and protein, and exhibit collagenase activity. Similarly, in guinea pigs exposed to cigarette smoke, MMPs are expressed by lung structural cells. However, it is important to note that expression of MMPs by alveolar epithelium or other structural cells does not necessarily lead to emphysema as it also occurs in interstitial lung diseases.

While intrapulmonary inflammation appears to be a consistent feature of smoking and emphysema, three recent studies in rodents illustrate that emphysema can develop with minimal or no inflammation. Rats exposed to agents that interfere with the function of vascular endothelial growth factor (VEGFR) receptors have apoptosis of alveolar epithelial cells and capillary endothelial cells and develop emphysema-like lungs. TIMP-3 “knockout” mice undergo pathological alveolar enlargement beginning around 2 weeks postpartum without an increase in inflammatory cells. A single intratracheal instillation of β-D-xyloside in rats is followed by disturbed proteoglycan synthesis, parenchymal destruction, and airspace enlargement comparable to that attained with intratracheal pancreatic elastase and it occurs without inflammation. The relevance of these models to human emphysema is not clear, but the models suggest that diverse homeostatic mechanisms are required to preserve normal lung structure.

What proteinases are responsible for alveolar septal destruction in emphysema? The diversity of inflammatory cell types in emphysematous tissue and the variety of proteinases produced by these cells raise the strong possibility that many proteinases might be involved in emphysematous lung destruction. This diversity also suggests that there might be differences between individuals and even in the same individual at different times. With the exception of emphysema associated with α₁-antitrypsin deficiency, in which NE appears to be the critical proteinase, conclusively identifying the key enzymes in emphysema pathogenesis has proved difficult. The present brief discussion will focus on neutrophil elastase and MMPs because these are the proteinases most associated with emphysema.

The possibility that NE is important in emphysema even among smokers with normal levels of α₁-antitrypsin has considerable support. For example, smoking increases NE in BAL fluid, and smokers with CT scan evidence of emphysema have higher levels of neutrophil specific proteinases including NE in their BAL fluid than smokers without emphysema. The role of NE in causing emphysema may be principally via its capacity to degrade the elastin in elastic fibres, but other mechanisms may also operate. Mice lacking NE as a result of
gene targeting show some protection from cigarette smoke induced emphysema caused by decreases in alveolar recruitment of neutrophils and monocytes, macrophage elastase activation, and degradation of TIMP-1, an inhibitor of macrophage elastase.68

Over the past few years MMPs have gained support as proteases involved in alveolar destruction in emphysema8 as this family of enzymes is associated with both physiological and pathological remodelling in many tissues including the lung.38 As a group, MMPs can degrade all components of the ECM. Members of the MMP family of enzymes are present in low to undetectable levels in normal lung, but are readily detected in many lung diseases. Macrophages can synthesise several MMPs. In contrast, neutrophils do not synthesise MMPs once they have completed their development in the bone marrow, but they carry in their granules two MMPs—MMP-2 (neutrophil collagenase) and MMP-9 (gelatinase B). It is important to note that the expression of MMPs is not restricted to inflammatory cells; virtually all cells including alveolar epithelial cells and fibroblasts can make MMPs. Also, the potential substrates of MMPs are not limited to ECM as many other proteins, including α1-antitrypsin, are also cleaved by these enzymes.39

Several MMPs have been implicated in the pathogenesis of emphysema (table 1). Interpretation of these data is difficult, however, because (1) most of them come from moderate or low to undetectable levels in normal lung, but are readily detected in many lung diseases. Macrophages can synthesise several MMPs. In contrast, neutrophils do not synthesise MMPs once they have completed their development in the bone marrow, but they carry in their granules two MMPs—MMP-2 (neutrophil collagenase) and MMP-9 (gelatinase B). It is important to note that the expression of MMPs is not restricted to inflammatory cells; virtually all cells including alveolar epithelial cells and fibroblasts can make MMPs. Also, the potential substrates of MMPs are not limited to ECM as many other proteins, including α1-antitrypsin, are also cleaved by these enzymes.39

### Table 1 Matrix metalloproteinases (MMPs) in human emphysema

<table>
<thead>
<tr>
<th>Author (ref)</th>
<th>Emphysema detection</th>
<th>Test samples</th>
<th>Observations</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finlay35</td>
<td>CT</td>
<td>AM mRNA and culture media</td>
<td>↑ collagenase 1 (MMP-1)</td>
<td>No increase in expression of macrophage elastase (MMP-12)</td>
</tr>
<tr>
<td>Finlay35</td>
<td>CT</td>
<td>BAL fluid</td>
<td>↑ collagenase activity</td>
<td>MMs probably neutrophil derived</td>
</tr>
<tr>
<td>Ohnishi40</td>
<td>Histology</td>
<td>Lung tissue from LVRS</td>
<td>↑ collagenase 2 (MMP-8), ↑ gelatinase B (MMP-9)</td>
<td>MMs in BAL fluid from inflammatory cells; no ↑ gelatinase B (MMP-9) in AM culture media in emphysema</td>
</tr>
<tr>
<td>Betuyuakii</td>
<td>CT</td>
<td>BAL fluid and AM culture media</td>
<td>↑ MT-MMP-1 (MMP-14), ↑ gelatinase B (MMP-9)</td>
<td>MMs are expressed by both inflammatory cells and structural cells of the lung</td>
</tr>
<tr>
<td>SeguraValdezii</td>
<td>Histology</td>
<td>Lung tissue from autopsy and-LVRS; BAL fluid</td>
<td>↑ collagenases 1, 2, 3 (MMPs-1, 8, -13)</td>
<td>Collagenase expressed by type II cells. No increase in expression of macrophage elastase (MMP-12)</td>
</tr>
<tr>
<td>Imaii</td>
<td>Histology</td>
<td>Lung tissue from lung transplant and LVRS</td>
<td>↑ collagenase 1 (MMP-1)</td>
<td>Collagenase expressed by type II cells. No increase in expression of macrophage elastase (MMP-12)</td>
</tr>
<tr>
<td>Minematsu43</td>
<td>CT</td>
<td>Cellular DNA</td>
<td>↑ gelatinase B (MMP-9) polymorphism in smokers with emphysema</td>
<td>This polymorphism also associated with an increased incidence of coronary atherosclerosis</td>
</tr>
</tbody>
</table>

CT=computed tomographic scan of the chest; AM=alveolar macrophage; BAL=bronchoalveolar lavage; LVRS=lung volume reduction surgery

neurphagelastase hypothesis pointed to elastin as the critical target of proteases that cause emphysema.42 Indeed, this emphasis was so dominant that the hypothesis has also been labelled the “elastase-antielastase” hypothesis.43 Clearly, destruction of alveolar elastin does lead to emphysema experimentally and frayed elastic fibres are evident in alveolar tissue in human emphysema.44 However, focus on the importance of elastic fibres has obscured the fact that destruction of alveolar walls affects other ECM components, of which collagens are the most prominent quantitatively and morphologically. Interestingly, when experiments involving intratracheal instillation of enzymes to produce emphysema were in vogue a few decades ago, none was done with mammalian collagenases nor have such experiments been done yet.

**Experimental studies as well as examinations of human tissue point to collagen breakdown and resynthesis in emphysema.**45 The likelihood that collagen turnover is a feature of the pathogenesis of emphysema is underscored by the prevalence of increased collagenolytic enzymes in human emphysema (table 1) and a small body of experimental data.46 Reductions in lung collagen can occur quickly in response to exposure to cigarette smoke, as increased levels of collagenous peptides are present in the BAL fluid of mice within 1 day of exposure to smoke from two cigarettes.47 However, with chronic exposure in mice there is increased lung collagen concurrent with the development of emphysema,48 results that match observations of increased lung collagen

**What alveolar septal ECM component(s) are targets in the pathogenesis of emphysema?**

Many of the early experimental studies supporting the proteinase-antiproteinase hypothesis pointed to elastin as the critical target of proteases that cause emphysema.42 Indeed, this emphasis was so dominant that the hypothesis has also been labelled the “elastase-antielastase” hypothesis.43 Clearly, destruction of alveolar elastin does lead to emphysema experimentally and frayed elastic fibres are evident in alveolar tissue in human emphysema.44 However, focus on the importance of elastic fibres has obscured the fact that destruction of alveolar walls affects other ECM components, of which collagens are the most prominent quantitatively and morphologically. Interestingly, when experiments involving intratracheal instillation of enzymes to produce emphysema were in vogue a few decades ago, none was done with mammalian collagenases nor have such experiments been done yet.

**Experimental studies as well as examinations of human tissue point to collagen breakdown and resynthesis in emphysema.**45 The likelihood that collagen turnover is a feature of the pathogenesis of emphysema is underscored by the prevalence of increased collagenolytic enzymes in human emphysema (table 1) and a small body of experimental data.46 Reductions in lung collagen can occur quickly in response to exposure to cigarette smoke, as increased levels of collagenous peptides are present in the BAL fluid of mice within 1 day of exposure to smoke from two cigarettes.47 However, with chronic exposure in mice there is increased lung collagen concurrent with the development of emphysema,48 results that match observations of increased lung collagen
content in human emphysema. Clearly, emphysema involves more than elastin degradation. Indeed, it is likely that the lung remodelling recognised as emphysema involves destruction and synthesis of all components of the lung ECM.

Authors' affiliations

J C Hogg, The University of British Columbia
Mcdonald Research Laboratory, St Paul's Hospital, Vancouver, Canada
R M Senior, Pulmonary and Critical Care Medicine, Department of Medicine, and Department of Cell Biology and Physiology, W ashington University School of Medicine and Barnes-Jewish Hospital, St Louis, Missouri, USA

JCH is supported in part by the Canadian Institutes of Health Research and the NHLBI/NIH. RMS is supported in part by NHLBI/NIH and the Canadian Institutes of Health Research and the NIH. AA and Edith L Wolff Charitable Trust.

REFERENCES

Chronic obstructive pulmonary disease c 2: Pathology and biochemistry of emphysema

J C Hogg and R M Senior

Thorax 2002 57: 830-834
doi: 10.1136/thorax.57.9.830

Updated information and services can be found at:
http://thorax.bmj.com/content/57/9/830

These include:

References
This article cites 46 articles, 11 of which you can access for free at:
http://thorax.bmj.com/content/57/9/830#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/